Bayer (ETR: BAYN), the German pharmaceutical and life sciences giant, has announced a strategic restructuring of its China business, carving it into five distinct business sectors and six functional departments. This reorganization is aimed at enhancing operational efficiency and strategic focus within the dynamic Chinese market.
The five business sectors include:
- The core product business team, which will oversee the commercial operations of key products such as Verquvo (vericiguat), Adalat (nifedipine), Xarelto (rivaroxaban), Bayaspirin (aspirin), Nimotop (nimodipine), Avelox (moxifloxacin), and Kovaltry (recombinant human coagulation factor VIII).
- A cardiovascular, renal, and metabolic business team handling the commercial operations for products like Kerendia (finerenone) and dorzagliatin.
- A women’s health business team dedicated to all women’s health products.
- A specialty medicine business team in charge of Eylea (aflibercept) and the entire oncology product portfolio.
- A retail business team responsible for the commercial operation of all prescription drugs in the retail channel.
The six functional departments comprise Dynamic Shared Ownership (DSO) transformation, medical affairs, market access, distributor management, commercial operation excellence, and a digital innovation team.
Bayer initiated the DSO operation model in January of this year with the goal of reducing hierarchical layers, eliminating bureaucratic obstacles, streamlining the organizational structure, and accelerating decision-making processes to be more agile and responsive to market needs.- Flcube.com
